Topotecan-pazopanib combination therapy for aggressive pediatric solid tumors
Posted in the Pediatric Cancer Forum
#1 Jul 27, 2011
A recent study reported in the journal Clinical Cancer Research, metronomic administration of Topotecan and pazopanib showed a statistically significant antitumor activity compared to respective single agents in pediatric tumor mouse models and represent a valid option as a maintenance therapy in aggressive pediatric solid tumors. In vitro, Topotecan caused a dose-dependent decrease in viabilities of all cell lines, while pazopanib did not. In vivo, combination of Topotecan + Pazopanib (TP+PZ) demonstrated significant anti-tumor activity and significant enhancement in survival compared to the respective single agents in all models. Pharmacokinetic studies of both drugs did not reveal any drug-drug interaction. News link: http://www.sciclips.com/sciclips/drug-discove...
Add your comments below
|Lemonade funrdaiser at UC Santa Cruz to support... (Mar '14)||Mar '14||jefry helms||5|
|Pediatric Cancer Foundation of the Lehigh Valle... (Dec '13)||Dec '13||PFfff||1|
|New Autism Registry Hopes to Boost Research Par... (Mar '13)||Sep '13||Conor||10|
|Stop & Shop brings back annual Triple Winner Game (Apr '11)||Sep '13||Ernesto||2|
|Terramed Alliance News Hope Street Kids joins C... (Oct '09)||Sep '13||Weston||8|
|Parents work for Childhood Cancer lic. plate (Jun '09)||Sep '13||Lincoln||3|
|Vallejo boy holds lemonade stand to raise money... (Jun '13)||Jun '13||Lamont Hightower||1|
Find what you want!
Search Pediatric Cancer Forum Now
Copyright © 2014 Topix LLC